AHA Scientific Sessions 2026 Abstract · Nov 2, 2026

Efficacy and Safety of Oral PCSK9 Inhibitors in Dyslipidemia: A Dose-Stratified Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

By Talkhan A, Abou Elezz AM, Hamouda M et al.

Background: Despite the availability of several lipid-lowering therapies, achieving optimal cholesterol control remains challenging in many patients with dyslipidemia. Although injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors provide substantial reductions in low-density lipoprotein cholesterol (LDL-C), their use may be limited by administration-related challenges and patient acceptance. Recently developed oral PCSK9 inhibitors represent a promising alternative; however, their comparative efficacy and safety across different dosing regimens have not been systematically evaluated. Methods: A comprehensive literature search was performed in PubMed, Scopus, the Cochrane Library, and Web of Science from database inception through March 31, 2026, to identify eligible randomized controlled trials (RCTs). Risk of bias was assessed using the ROB-2 tool, and all analyses were conducted in R. The primary outcome was the mean percentage change from baseline in LDL-C levels. Secondary outcomes included the mean percentage change from baseline in non–high-density lipoprotein cholesterol (non-HDL-C), total cholesterol, apolipoprotein B, and safety outcomes. Results: Five RCTs comprising 4,227 participants met the inclusion criteria. In the dose-stratified network meta-analysis, NNC0385-0434 100 mg produced the greatest reduction in LDL-C compared with placebo (MD = –61.80%, 95% CI [–78.10, –45.50]; SUCRA = 0.85), followed closely by MK-0616 30 mg (MD = –60.90%, 95% CI [–74.98, –46.82]; SUCRA = 0.84), MK-0616 18 mg (SUCRA = 0.80), and MK-0616 20 mg (SUCRA = 0.79). Significant dose-dependent reductions were also observed in non-HDL-C, total cholesterol, lipoprotein(a), and apolipoprotein B. In addition, MK-0616 20 mg and NNC0385-0434 100 mg significantly increased HDL-C. Oral PCSK9 inhibitors markedly improved LDL-C goal attainment, with MK-0616 20 mg ranking highest (RR = 45.07, 95% CI [27.70, 73.35]). Furthermore, these agents did not increase the risk of adverse events and were associated with a lower incidence of fatigue. Conclusion: Oral PCSK9 inhibitors provide substantial lipid-lowering efficacy, significantly improve LDL-C target achievement, and demonstrate a favorable safety profile compared with placebo. These findings support their potential role as effective oral alternatives for the management of dyslipidemia.

doi.org/10.1161/circ.154.suppl_1.15656Interventions

AgingResearch.News